Why Vir Biotechnology Stock Soared Today
Shares of Vir Biotechnology (NASDAQ: VIR) surged 32% on Tuesday after the immunology company announced promising clinical trial results for its COVID-19 antibody treatment.
Vir and its partner GlaxoSmithKline (NYSE: GSK) said an independent data monitoring committee recommended that they stop their phase 3 study of VIR-7831 early, as the experimental therapy demonstrated "profound efficacy."
Investors bid up Vir Biotechnology's stock price on Thursday. Image source: Getty Images.
Source Fool.com
